• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Human PBMC Model Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Human peripheral blood mononuclear cells (PBMCs) are routinely used in vitro to detect cytokine secretion as part of preclinical screens to delineate antagonistic as well as agonistic action of drug candidates. With the current trend of developing immune-modulatory therapeutics for various oncology and autoimmune indications, Creative Biolabs aims to provide additional information about clients' molecule before proceeding to clinical trials. We provide human PBMCs model development and immunogenicity assays to promote your cytokine release syndrome (CRS) project.

Human PBMCs Introduction

Human PBMCs are found in the peripheral blood circulating throughout the body and not sequestered in the lymphatic system, spleen, liver or bone marrow. PBMCs are composed of four cell types: B cells, T cells, natural killer (NK) cells and monocytes. One of the applicable research areas is the evaluation of inflammatory response orchestrated by cytokines and chemokines. CRS are potentially fatal immune reactions characterized by large-scale release, upon the infusion of therapeutic candidates, of the proinflammatory cytokines IL-2, IL-4, IL-6, IL-8, IL-17, TNF-a, IFN gamma by immune cells. In vitro test systems using human blood cells have been proposed and are applied non-clinically to evaluate the potential risk of CRS. Two basis assay formats are routinely used: stimulation of human PBMC with immobilized test articles, and of whole blood (WB) cells with aqueous test articles. Co-culture of PBMCs on HUVECs and pre-culture of PBMCs at high cell density are two improved measures to predict CRS.

Fig.1 Solid phase cytokine release assay (CRA). (Finco, 2014)

Model Establishment and Optimization

Creative Biolabs has optimized human PBMC systems to provide an environment in which soluble monoclonal antibodies (mAbs) are free to interact with a selection of cells that are most likely seen in vivo. Such an environment could indicate the potential of a mAb-induced CRS response that was mediated through a variety of mechanisms. We offer a comprehensive set of PBMC model development and further CRA services for our honor clients.

• The standard proinflammatory cytokine panel include cytokines of the adaptive and the innate arm: IFN gamma, IL-2, IL-6, IL-8 and TNF-a.
• Optional analytes can be included in the cytokine evaluation if you wish.

At Creative Biolabs, multiple quality controls are performed for PBMC model, certifying their virologic conformity and viability. Once isolated, the cells are frozen in featured medium. Mycoplasma and virologic detection tests are performed on all batches. A full certificate of analysis will be provided for each batch of PBMCs cells. For CRA assays, Creative Biolabs will promote your projects in the following points:

• Help predict cytokine release induced by therapeutics in safety studies.
• Assess cytokine release with immunogenicity assays in response to therapeutic molecules using appropriately designed studies based on our rich experience.
• Our high throughput system and workflow with qualified donors give you high quality results with rapid turnaround.
• Data is provided in optional formats, such as raw data or PDF summary.

If you are interested in our human PBMCs model for CRS research, please feel free to contact us to find suitable products and services to support your specific program.

Reference

1. Finco, D.; et al. Cytokine release assays: current practices and future directions. Cytokine. 2014, 66(2): 143-155.